{"id":692312,"date":"2022-10-05T08:05:05","date_gmt":"2022-10-05T12:05:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\/"},"modified":"2022-10-05T08:05:05","modified_gmt":"2022-10-05T12:05:05","slug":"pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\/","title":{"rendered":"Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary\/Lung Disease Mini-Symposium"},"content":{"rendered":"
\n

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, and Greg Cosgrove, M.D., FCCP, Vice President, Clinical Development, will\u00a0present a corporate overview at the Pulmonary\/Lung Disease Mini-Symposium, a part of RBC\u2019s Biotech Expert Insights Series.<\/p>\n

Details of the virtual presentation:<\/p>\n

\n Date:<\/strong> Friday, October 7, 2022<\/p>\n

\n Time:<\/strong> 10:20 a.m. ET | 7:20 a.m. PT<\/p>\n

\n Fireside Chat:<\/strong>
\n https:\/\/www.veracast.com\/webcasts\/rbc\/lung2022\/568XeZ.cfm<\/a>\n <\/p>\n

The RBC Mini-Symposium will include company presentations and sessions with key opinion leaders from across several lung disease areas including sarcoidosis, scleroderma, and idiopathic pulmonary fibrosis (IPF).<\/p>\n

Interested parties can access the live and replay versions of\u00a0Pliant\u2019s corporate overview from the Investor Relations\u2019 Events & Presentation page of Pliant\u2019s website at\u00a0https:\/\/ir.pliantrx.com\/news-and-events\/events-and-presentations<\/a>\u00a0with an audio archive available for 30 days from the time it is made available. Those interested in registering for the KOL sessions should contact their RBC sales representative.<\/p>\n

\n About Pliant Therapeutics, Inc.<\/strong>\n <\/p>\n

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant’s lead product candidate, PLN-74809, is an oral small molecule dual selective inhibitor of \u03b1v\u00df6 and \u03b1v\u00df1 integrins that is currently in development for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in PSC. Pliant is currently conducting Phase 2a trials of PLN-74809 in IPF and PSC. Pliant has also developed PLN-1474, a Phase 2-ready small molecule selective inhibitor of \u03b1v\u00df1 for the treatment of nonalcoholic steatohepatitis, or NASH, with liver fibrosis, which Pliant has partnered with Novartis. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics,\u00a0visit <\/a>www.pliantrx.com<\/a>\u00a0and follow us on Twitter<\/a>, LinkedIn<\/a>,\u00a0Facebook<\/a> and\u00a0YouTube<\/a>.<\/p>\n

\n Investor and Media Contact:<\/strong>\n <\/p>\n

Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, and Greg Cosgrove, M.D., FCCP, Vice President, Clinical Development, will\u00a0present a corporate overview at the Pulmonary\/Lung Disease Mini-Symposium, a part of RBC\u2019s Biotech Expert Insights Series. Details of the virtual presentation: Date: Friday, October 7, 2022 Time: 10:20 a.m. ET | 7:20 a.m. PT Fireside Chat: https:\/\/www.veracast.com\/webcasts\/rbc\/lung2022\/568XeZ.cfm The RBC Mini-Symposium will include company presentations and sessions with key opinion leaders from across several lung disease areas including sarcoidosis, scleroderma, and idiopathic pulmonary fibrosis (IPF). Interested parties … <\/p>\n

Continue reading “Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary\/Lung Disease Mini-Symposium”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-692312","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary\/Lung Disease Mini-Symposium - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary\/Lung Disease Mini-Symposium - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, and Greg Cosgrove, M.D., FCCP, Vice President, Clinical Development, will\u00a0present a corporate overview at the Pulmonary\/Lung Disease Mini-Symposium, a part of RBC\u2019s Biotech Expert Insights Series. Details of the virtual presentation: Date: Friday, October 7, 2022 Time: 10:20 a.m. ET | 7:20 a.m. PT Fireside Chat: https:\/\/www.veracast.com\/webcasts\/rbc\/lung2022\/568XeZ.cfm The RBC Mini-Symposium will include company presentations and sessions with key opinion leaders from across several lung disease areas including sarcoidosis, scleroderma, and idiopathic pulmonary fibrosis (IPF). Interested parties … Continue reading "Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary\/Lung Disease Mini-Symposium"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-05T12:05:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTEzMyM1MTg3NDIxIzIxODU0NzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary\\\/Lung Disease Mini-Symposium\",\"datePublished\":\"2022-10-05T12:05:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\\\/\"},\"wordCount\":396,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTEzMyM1MTg3NDIxIzIxODU0NzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\\\/\",\"name\":\"Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary\\\/Lung Disease Mini-Symposium - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTEzMyM1MTg3NDIxIzIxODU0NzY=\",\"datePublished\":\"2022-10-05T12:05:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTEzMyM1MTg3NDIxIzIxODU0NzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1OTEzMyM1MTg3NDIxIzIxODU0NzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary\\\/Lung Disease Mini-Symposium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary\/Lung Disease Mini-Symposium - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\/","og_locale":"en_US","og_type":"article","og_title":"Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary\/Lung Disease Mini-Symposium - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, and Greg Cosgrove, M.D., FCCP, Vice President, Clinical Development, will\u00a0present a corporate overview at the Pulmonary\/Lung Disease Mini-Symposium, a part of RBC\u2019s Biotech Expert Insights Series. Details of the virtual presentation: Date: Friday, October 7, 2022 Time: 10:20 a.m. ET | 7:20 a.m. PT Fireside Chat: https:\/\/www.veracast.com\/webcasts\/rbc\/lung2022\/568XeZ.cfm The RBC Mini-Symposium will include company presentations and sessions with key opinion leaders from across several lung disease areas including sarcoidosis, scleroderma, and idiopathic pulmonary fibrosis (IPF). Interested parties … Continue reading \"Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary\/Lung Disease Mini-Symposium\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-05T12:05:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTEzMyM1MTg3NDIxIzIxODU0NzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary\/Lung Disease Mini-Symposium","datePublished":"2022-10-05T12:05:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\/"},"wordCount":396,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTEzMyM1MTg3NDIxIzIxODU0NzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\/","name":"Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary\/Lung Disease Mini-Symposium - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTEzMyM1MTg3NDIxIzIxODU0NzY=","datePublished":"2022-10-05T12:05:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTEzMyM1MTg3NDIxIzIxODU0NzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1OTEzMyM1MTg3NDIxIzIxODU0NzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-rbc-biotech-expert-insights-series-pulmonary-lung-disease-mini-symposium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary\/Lung Disease Mini-Symposium"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692312","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=692312"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692312\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=692312"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=692312"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=692312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}